- Home
- IOBT vs IMMX Comparison
IOBT vs IMMX Comparison
Compare IOBT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- IMMX
- Stock Information
- Founded
- IOBT 2014
- IMMX 2014
- Country
- IOBT Denmark
- IMMX United States
- Employees
- IOBT N/A
- IMMX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- IOBT Health Care
- IMMX Health Care
- Exchange
- IOBT Nasdaq
- IMMX Nasdaq
- Market Cap
- IOBT 57.9M
- IMMX 50.1M
- IPO Year
- IOBT 2021
- IMMX 2021
- Fundamental
- Price
- IOBT $1.16
- IMMX $1.70
- Analyst Decision
- IOBT Strong Buy
- IMMX Strong Buy
- Analyst Count
- IOBT 3
- IMMX 1
- Target Price
- IOBT $9.33
- IMMX $7.00
- AVG Volume (30 Days)
- IOBT 213.3K
- IMMX 46.2K
- Earning Date
- IOBT 05-13-2025
- IMMX 05-08-2025
- Dividend Yield
- IOBT N/A
- IMMX N/A
- EPS Growth
- IOBT N/A
- IMMX N/A
- EPS
- IOBT N/A
- IMMX N/A
- Revenue
- IOBT N/A
- IMMX N/A
- Revenue This Year
- IOBT $59.29
- IMMX N/A
- Revenue Next Year
- IOBT N/A
- IMMX N/A
- P/E Ratio
- IOBT N/A
- IMMX N/A
- Revenue Growth
- IOBT N/A
- IMMX N/A
- 52 Week Low
- IOBT $0.66
- IMMX $1.26
- 52 Week High
- IOBT $1.79
- IMMX $3.13
- Technical
- Relative Strength Index (RSI)
- IOBT 67.95
- IMMX 45.15
- Support Level
- IOBT $0.90
- IMMX $1.64
- Resistance Level
- IOBT $1.37
- IMMX $1.90
- Average True Range (ATR)
- IOBT 0.10
- IMMX 0.14
- MACD
- IOBT 0.03
- IMMX 0.01
- Stochastic Oscillator
- IOBT 60.97
- IMMX 29.47
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.